VERAXA Biotech (NASDAQ: VRXA) has announced a significant milestone in its oncology pipeline, revealing that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This progress follows the completion of the discovery portion of the company’s collaboration with OmniAb Inc., which began in May 2025. With the discovery work now finished, VERAXA will focus on engineering the final therapeutic candidate by integrating the antibody binders identified through the collaboration with its proprietary antibody engineering, linker, and conjugation technologies.
Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages the company’s expertise in antibody engineering and conjugation chemistry, making it one of the more advanced programs in its pipeline. The advancement of VXA-222 underscores VERAXA’s commitment to developing novel cancer therapies for difficult-to-treat malignancies.
In parallel with this development milestone, VERAXA has expanded its intellectual property portfolio. The company recently filed its first patent applications related to its BiTAC platform, along with additional patents covering conjugation chemistry, payloads, and antibody technologies. As a result, VERAXA now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. The newly filed applications are expected to extend protection into at least 2047, safeguarding the company’s innovations in the competitive field of antibody-based cancer therapeutics.
This dual progress—advancing a key pipeline candidate and strengthening its IP position—positions VERAXA to capitalize on its research and development efforts. The company continues to build a diversified oncology pipeline that spans bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats, all aimed at addressing cancers that are currently difficult to treat.
The completion of the discovery phase with OmniAb is a testament to the collaborative work between the two companies. As VERAXA moves VXA-222 into preclinical validation, it will be critical to demonstrate the efficacy and safety of the candidate in preclinical models. Success in these studies could pave the way for clinical trials, bringing the company closer to offering new treatment options for patients.
Investors and industry observers will be watching VERAXA’s next steps closely, as the company’s progress in both its pipeline and intellectual property could have significant implications for its competitive standing. The expansion of the patent portfolio not only protects existing technologies but also provides a foundation for future innovations, potentially creating barriers to entry for competitors.
VERAXA’s announcement comes at a time when the biotech sector is increasingly focused on next-generation antibody technologies. The company’s efforts to advance VXA-222 and secure its intellectual property demonstrate a strategic approach to developing novel therapies. As the program moves forward, further updates on preclinical results and regulatory milestones will be crucial in assessing the company’s trajectory.
For more information on VERAXA and its latest developments, the company’s newsroom is available at https://ibn.fm/VRXA.
